Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kite long-term follow-up study for participants previously treated with gene-modified cells
NL-OMON51477Phase 3Recruiting
- Sponsor
- Kite Pharma
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in B-cell malignancy, sponsored by Kite Pharma. Primary endpoints: Late-onset targeted adverse events and serious adverse events, Mechanism of RCR/RCL or insertional mutagenesis and 1 more. Started Dec 2022; status: recruiting.
02
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NL-OMON51477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51477.